Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

ARNA 1.68 -0.03 (-1.75%)
price chart
Analyst's Stocks Ratings Trend: GlaxoSmithKline PLC (NYSE:GSK) , Arena ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed bullish move with gain of +2.40% after exchanging volume of 2.32 million shares in last trading session ended on 7/27/2016.
The Insider Activity Don't Lie: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) down -2.91 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) added about 5.1 percent in value ...  Zergwatch
Review Analyst's saying: AbbVie Inc. (NYSE:ABBV) , Arena Pharmaceuticals ...  Is stories
Biotech Stocks Worth Chasing: Celgene Corp. (CELG), Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc. (ARNA) recently recorded 0.6 percent change and currently at $1.67 is 28.46 percent away from its 52-week low and down -59.95 percent versus its peak.
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Arena Pharmaceuticals Inc. ARNA, -5.62% shares rose 8.8% in pre-market trade Tuesday after the company said its weight-loss drug with Eisai Inc. 4523, +0.46% received Food and Drug Administration approval.
Hot Biotech Stocks To Watch Right Now: Celldex Therapeutics, Inc. (CLDX ...
Arena Pharmaceuticals, Inc. (ARNA) recently recorded 2.4 percent change and currently at $1.71 is 31.54 percent away from its 52-week low and down -58.99 percent versus its peak.
Biotech Stocks Worth a Closer Look: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) climbed 2.4% by the end of recent close at $1.71. For the ongoing quarter, the 6 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of -$0.1/share, which would ...
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S.
Arena - Belviq Scripts Start Q3 In Tough Shape  Seeking Alpha
Arena Pharmaceuticals Inc Stock Technicals at Critical Inflection Point
This is a technical analysis stock rating for Arena Pharmaceuticals Inc (NASDAQ:ARNA) . The company has a three bull technical rating which indicates an inflection point.
Company Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc. announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI´┐Ż(lorcaserin HCl: ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Receives Consensus Rating of " ...  BBNS
Arena Pharmaceuticals boosted as obesity drug gets Mexican approval  Proactive Investors USA & Canada
Two Stocks within Analysts Review: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) diminished -5.62%, closing at $1.68 after floating between $1.68 and $1.79.
Latest Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Target Price Suggests Stock ...  Review Fortune
Trading the Biotech News: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Biogen ...  The Voice Registrar